ABT Will Produce Triple Agarose-Bead Production

ABT Will Produce Triple Agarose-Bead Production ...

Purification of a product with chromatography is a key downstream component in bioprocessing. Using a resin, such as agarose, the process can be extracted from red seaweed. Agarose Bead Technologies (ABT) has announced that it will triple its production capacity for making agarose resins.

Bioprocessors could not produce therapeutics if necessary, because crucial steps, such as purification, could not be accomplished. Following supply-chain challenges during the first two years of COVID-19, many vendors are planning to increase manufacturing volumes.

ABT will increase the production of various agarose beads via a proprietary process. Non-activated agarose beads, which can be used in size exclusion chromatography, and activated agarose beads, which can be used in affinity and ion exchange chromatography.

ABT plans to complete an additional 1,000 square meters of production space, based on GMP-compliant and large-capacity bioreactors that ABT will use to make activated and non-activated agarose beads. ABT's general manager claims that the new facilities' continuous manufacturing capacity and improved scalability are expected to save time to market, while reducing capital and operating costs.

The COVID-19 epidemic might be the value of being prepared.

ABT continues to strengthen its manufacturing capabilities to establish and ensure the worldwide supply of raw material for new emerging therapies' production processes, according to Egea.

You may also like: